The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative131I dose over 37 GBq

2014 ◽  
Vol 83 (1) ◽  
pp. 117-123 ◽  
Author(s):  
Ah Reum Khang ◽  
Sun Wook Cho ◽  
Hoon Sung Choi ◽  
Hwa Young Ahn ◽  
Won Sang Yoo ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patients ◽  
Differentiated Thyroid Cancer ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy

scholarly journals Is radioactive iodine- 131 treatment related to the occurrence of non-synchronous second primary malignancy in patients with differentiated thyroid cancer?

2016 ◽  
Vol 60 (1) ◽  
pp. 9-15 ◽  
Author(s):  
Marcelo Cruzick de Souza ◽  
Denise P. Momesso ◽  
Fernanda Vaisman ◽  
Leonardo Vieira Neto ◽  
Rosangela Aparecida Gomes Martins ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Iodine 131 ◽  
Radioactive Iodine 131

scholarly journals Risk of Second Primary Malignancy in Patients Treated with Radioactive Iodine for Thyroid Cancer

2021 ◽  
Author(s):  
K McNamara ◽  
Veronica Barry ◽  
Alexander Yao ◽  
Joanne Weekes ◽  
Thomas Saunders ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Total Thyroidectomy ◽  
Neck Dissection ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Recurrence Rates ◽  
Primary Malignancy ◽  
Increased Risk

ABSTRACT Introduction Radioactive iodine (RAI) is widely used as a treatment for differentiated thyroid cancer following total thyroidectomy. There is a risk of second primary malignancy (SPM) in these patients which is estimated between 0-5% although research to support this is limited. The primary aim of this study was to ascertain the rate of SPM in patients who have undergone RAIT for thyroid cancer. The secondary objectives were to assess whether the risk is dose dependant and examine the overall survival and recurrence rates. Methods A retrospective review of all patients treated with radioactive iodine for thyroid cancer between 2002 and 2014. Patient information was collected from a structured database. Data regarding second cancers and recurrence rates was obtained from an online clinical portal. Follow up was 5 years minimum. Results 199 patients underwent RAI treatment. Median age was 53. 71.4% patients were female and 28.6% were male. All patients underwent total thyroidectomy. 13.6% underwent total thyroid and central neck dissection. 11% underwent total thyroidectomy and lateral neck dissection. 5.5% required post-operative radiotherapy. 12% patients developed recurrent thyroid cancer. 8% developed a SPM of which prostate, skin, head and neck SCC were the most common. A dose ≥3.7 (Gigabecquerel) GBq was statistically significantly more likely to lead to a SPM with a P value of 0.041 (95% CI -0.52 – 0.01318). Conclusions Increased risk of developing a second primary malignancy should be taken into account, especially in younger patients with low risk disease, when deciding on RAIT. Key words Radioactive iodine, Differentiated thyroid cancer, Second primary malignancy, Radioiodine, Thyroid cancer

Occurrence of second primary malignancy in medullary thyroid cancer (MTC) patients

2019 ◽  
Author(s):  
George Simeakis ◽  
Katerina Saltiki ◽  
Evangelia Zapanti ◽  
Evanthia Kassis ◽  
Maria Alevizaki
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Medullary Thyroid

scholarly journals Second Primary Malignancy Risk After Radioactive Iodine Treatment for Thyroid Cancer: A Systematic Review and Meta-analysis

Thyroid ◽  
2009 ◽  
Vol 19 (5) ◽  
pp. 451-457 ◽  
Author(s):  
Anna M. Sawka ◽  
Lehana Thabane ◽  
Luciana Parlea ◽  
Irada Ibrahim-Zada ◽  
Richard W. Tsang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Thyroid Cancer ◽  
Radioactive Iodine ◽  
Meta Analysis ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Malignancy Risk ◽  
Iodine Treatment
Sign in / Sign up

Export Citation Format

Share Document